硫化聚乙基膜嵌入了纳利迪克斯酸 - - 一种新兴的受控药物释放器
Himabindu Padinjarathil1,2, Vidya Vilasini1, Rajalakshmi Balasubramanian1
1Dhanvanthri Laboratory, Department of Sciences, Amrita School of Physical Sciences, Amrita Vishwa Vidyapeetham, Coimbatore 641112, India.
Polymers
|September 9, 2023
概括
硫聚基 (SPEK) 膜为持续的药物输送提供了一个新的解决方案,克服了破裂释放在伤口愈合中的局限性. 这些生物相容膜表现出受控的药物释放动力学和低毒性.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 药物输送系统 药物输送系统
背景情况:
- 目前的药物管理方法面临突发释放和不良同化方面的挑战,影响治疗疗效,特别是在伤口愈合方面.
- 聚合物,特别是聚乙烯基 (PEEK) 家族,由于其生物相容性和惰性等有利性质,在生物医学研究中得到了广泛的探索.
- 聚乙基 (PEK) 是PEEK家族的一种成员,具有作为药物载体的潜力,但其水友性需要增强,以便有效的药物加载和释放.
研究的目的:
- 通过硫化使聚乙基 (PEK) 功能化,以提高其水友性,并探索其作为药物输送载体的潜力.
- 使用响应表面方法 (RSM) 优化PEK的硫化过程.
- 制造和表征硫化聚乙基 (SPEK) 膜,用于持续释放药物的应用.
主要方法:
- 聚乙基 (PEK) 使用硫酸进行硫化,该过程通过响应表面方法 (RSM) 考虑时间,温度和硫化程度来优化.
- 使用逆位定位量化硫化效率,达到69%的最大硫化效率.
- 制造了含有纳利迪克斯盐的硫化聚乙基 (SPEK) 膜,并评估了它们的药物释放特征,生理性质,形态学,血液溶解和体外细胞毒性.
主要成果:
- 优化的硫化产生了增强水友性的SPEK.
- 在蒸水和模拟体液中,SPEK膜在24小时内表现出受控的零顺序药物释放动力学.
- 在Vero细胞系的体外细胞毒性测试中,SPEK膜的毒性较低,血液溶解低,生物相容性良好 (IC50: 137.85 g/mL).
结论:
- 硫聚基 (SPEK) 膜对于持续的药物输送是有效的.
- 开发的SPEK膜显示出有希望的生物相容性和受控释放特性,解决了传统药物载体的局限性.
- 这些发现凸显了SPEK膜作为治疗应用的先进材料的潜力,特别是在伤口愈合和局部药物输送方面.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...